Company Overview
Company Type: Public Company
Website: www.mindsetpharma.com
Number of Employees: -
Ticker: MSET (CNSX)
Year Founded: -


Business Description
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
7.8
Market Capitalization
75.0
TEV/Total Revenue
8.8x
Total Enterprise Value
67.9
TEV/EBITDA
NM
EBIT
(5.4)
Cash & ST Invst.
7.3
P/Diluted EPS Before Extra
NM
Net Income
(6.1)
Total Debt
0.1
Price/Tang BV
NM
Total Assets
8.7
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Mar-31-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023


Estimates Snapshot (Current Fiscal Year End: Jun-30-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.03)
(0.03)
(0.09)
(0.15)
(0.12)
Revenue (mm)
2.65
0.00
8.75
10.50
2.65
EBITDA (mm)
(2.65)
-
(7.50)
(23.55)
(19.54)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
7.75x
TEV/EBITDA
NM

Non-Periodic Estimates

Recommendation
Outperform (2.00)
Target Price
1.25
Potential Upside
68.92%


Key Professionals
Name
Title
Lanthier, James Andre-Charles
Chief Executive Officer
Ramos, Arvin 
Chief Financial Officer
Araujo, Joseph 
Chief Scientific Officer, Member of Scientific Advisory Board & Director
Atkinson, Jason 
Head of Corporate Development
Slassi, Abdelmalik 
Senior VP of Innovation & Member of Scientific Advisory Board
Irwin, Chris 
Corporate Secretary

Key Board Members
Name
Title
Patricio, Richard J.
Independent Chairman
Araujo, Joseph 
Chief Scientific Officer, Member of Scientific Advisory Board & Director
Slassi, Abdelmalik 
Senior VP of Innovation & Member of Scientific Advisory Board
Dean, Ian 
Former Director of Preclinical & Member of Scientific Advisory Board
Gabriele, Joseph 
Member of Scientific Advisory Board
Husain, Ishrat 
Member of Scientific Advisory Board
Kandil, Ali 
Member of Scientific Advisory Board
Passin, James Christopher
Independent Director
Rogawski, Michael 
Member of Scientific Advisory Board
Williams, Philip 
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
217 Queen Street West Suite 401 | Toronto, ON | M5V 0R2 | Canada

Current and Pending Investors
McQuade Center for Strategic Research and Development, LLC, Negev Capital, Ontario Brain Institute, Otsuka America, Inc. (Pending)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.74
Market Cap (mm)
75.0
Open
 0.74
Shares Out. (mm)
101.3
Previous Close
 0.74
Float %
73.8%
Change on Day
0.01
Shares Sold Short (mm)
-
Change % on Day
1.4%
Dividend Yield %
-
Day High/Low
 0.74/ 0.73
Diluted EPS Excl. Extra Items
(0.06)
52 wk High/Low
 0.74/ 0.22
P/Diluted EPS Before Extra
NM
Volume (mm)
0.05
Avg 3M Dly Vlm (mm)
0.17
Beta 5Y
(0.10)


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
CNSX:MSET - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
North Sur Resources Inc.
North Sur Resources Inc. ("North Sur" or the "Corporation") was incorporated under the Business Corporations Act (Alberta) on January 12, 2011 and is in the business of acquiring, exploration and developing mineral exploration properties. To date, the Corporation has not generated revenues from operations.

United States and Canada
Diversified Metals and Mining
-
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-01-2023
-
Merger/Acquisition
Target
Mindset Pharma Inc. (CNSX:MSET)
Otsuka America, Inc.

60.04
Jan-05-2022
Jan-05-2022
Private Placement
Target
Mindset Pharma Inc. (CNSX:MSET)
McQuade Center for Strategic Research and Development, LLC

5.00
Mar-22-2021
Apr-15-2021
Public Offering
Target
Mindset Pharma Inc. (CNSX:MSET)


5.98
Nov-09-2020
Dec-15-2020
Private Placement
Target
Mindset Pharma Inc. (CNSX:MSET)
Ontario Brain Institute

-
Jun-29-2020
Sep-11-2020
Merger/Acquisition
Buyer
North Sur Resources Inc.
Mindset Pharma Inc. (CNSX:MSET)
Bluesky Equities Ltd.
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-01-2023
M&A Transaction Announcements
Otsuka America, Inc. entered into a definitive agreement to acquire Mindset Pharma Inc. (CNSX:MSET) for CAD 75.9 million.
Jun-22-2023
Product-Related Announcements
Mindset Pharma Inc. Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder
Apr-26-2023
Product-Related Announcements
Mindset Pharma Inc. Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds
Apr-05-2023
Company Conference Presentations
Mindset Pharma Inc. Presents at Sequire Cannabis & Psychedelics Conference, Apr-05-2023 01:30 PM
Mar-17-2023
Annual General Meeting
Mindset Pharma Inc., Annual General Meeting, Mar 17, 2023

M&A Advisors
Echelon Wealth Partners Inc., Irwin Lowy LLP, Nauth LPC, Wildeboer Dellelce LLP


Advisors
Most Recent Auditor
MNP LLP
M&A Advisors
Echelon Wealth Partners Inc., Irwin Lowy LLP, Nauth LPC, Wildeboer Dellelce LLP
Private Placement Advisors
Research Capital Corporation, Wildeboer Dellelce LLP
Public Offering Advisors
Irwin Lowy LLP, MNP LLP


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
H.C. Wainwright & Co.
Trucchio, Patrick Ralph
Jun 30, 2023 10:00 AM
MSET
Psychedelic Program MSP-1014 Could Emerge as Differentiated Depression Treatment; Collaborations on Track; Reiterate Buy
EPS Estimates*
11
Echelon Wealth Partners Inc.
Quenneville, Stefan
May 31, 2023 05:37 AM
MSET
MSET - FQ323 Cash Burn In Line; Patent Lawsuit Appears Baseless but Validates Value of IP; Reiterating Spec. Buy and $1.25 TP
Notes
6
H.C. Wainwright & Co.
Trucchio, Patrick Ralph
Mar 23, 2023 04:11 AM
MSET
Advances Multiple Psychoactive Compounds to Clinical Development; Augments IP Protection; Reiterate Buy
EPS Estimates*
8
Echelon Wealth Partners Inc.
Quenneville, Stefan
Feb 24, 2023 09:21 AM
MSET
MSET - FQ223 In-Line; Strengthening IP Position & Ongoing Clinical Progress Underlie Our Positive Outlook; Reiterating Spec. Buy and $1.25 PT
Reporting Results*
5
Echelon Wealth Partners Inc.
Quenneville, Stefan
Nov 30, 2022 05:17 AM
MSET
MSET - FQ123 Cash Burn In-Line as Mindset Looks to Enter the Clinic in Early C2023; Reiterating Spec. Buy and $1.25 TP
Notes
5
H.C. Wainwright & Co.
Trucchio, Patrick Ralph
Nov 17, 2022 04:06 AM
MSET
HCW "At Home" Recap: Reiterate Buy Ahead of Advancement of Lead Psychedelic Compound MSP-1014 to Clinical Development
EPS Estimates*
9
Echelon Wealth Partners Inc.
Quenneville, Stefan
Oct 27, 2022 05:48 AM
MSET
MSET - FQ4 Cash Burn In Line as Mindset Continues to Progress Towards the Clinic; Reiterating Spec. Buy and $1.25 TP
Notes
5
Echelon Wealth Partners Inc.
Quenneville, Stefan
Sep 27, 2022 09:46 AM
MSET
MSET - The Trip is Just Beginning: Cybin Licensing Deal Validates Mindset’s Strong IP Position; Reiterating Spec. Buy and $1.25 TP
Notes
5
Echelon Wealth Partners Inc.
Quenneville, Stefan
Jul 06, 2022 05:00 PM
MSET
MSET - Initiating Coverage – The Grateful Meds: Next-Gen Psychedelics, Industry-Leading IP, and a Big Pharma Partner Along for the Trip
Initiation of Coverage*
53
H.C. Wainwright & Co.
Trucchio, Patrick Ralph
Jun 06, 2022 04:06 AM
MSET
Well-Positioned to Shine With Multiple Novel Psychoactive Agents Nearing Phase 1 Development; Reiterate Buy
EPS Estimates*
9


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Negev Capital

6,087,000

6.01

4.5

Mar-17-2023


Patricio L.L.B., LL.B., Richard J.

3,849,083

3.80

2.8

Aug-31-2023


Irwin B.A., L.L.B., L.L.M., LL.M., LLB, Q.C., Christopher E.O.

3,282,687

3.24

2.4

Aug-31-2023


Passin, James Christopher

3,047,000

3.01

2.3

Aug-31-2023


Atkinson, Jason 

2,782,950

2.75

2.1

Aug-31-2023


Williams (Commerce), B.Com., B.Comm. CFA, C.F.A., CFA, Philip 

2,739,950

2.70

2.0

Aug-31-2023


Lanthier, James Andre-Charles

2,731,500

2.70

2.0

Aug-31-2023


Slassi Ph.D., Abdelmalik 

1,523,500

1.50

1.1

Aug-31-2023


Irwin Professional Corporation

380,875

0.38

0.3

Aug-31-2023


Araujo, Joseph 

90,000

0.09

0.1

Aug-31-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Irwin B.A., L.L.B., L.L.M., LL.M., LLB, Q.C., Christopher E.O.
3,282,687
3,282,687
Atkinson, Jason 
2,782,950
2,782,950
Irwin Professional Corporation
380,875
380,875
Araujo, Joseph 
90,000
26,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Mirae Asset Global Investments Co., Ltd.
0
(674,347)
Patricio L.L.B., LL.B., Richard J.
3,849,083
(542)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
cGMP Psilocybin, MSP-1014 (Future), Psychedelic Compounds


Upcoming Events
Date/Time
Type
Oct-19-2023
Special/Extraordinary Shareholders Meeting
Oct-27-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Oct-05-2023
Mindset Pharma Inc. (CNSX:MSET)
SEDAR
News Releases
202 KB
Sep-22-2023
Mindset Pharma Inc. (CNSX:MSET)
SEDAR
Management Proxy Materials
141 KB
Sep-22-2023
Mindset Pharma Inc. (CNSX:MSET)
SEDAR
Management Proxy Materials
108 KB
Sep-22-2023
Mindset Pharma Inc. (CNSX:MSET)
SEDAR
Management Proxy Materials
2 MB
Sep-22-2023
Mindset Pharma Inc. (CNSX:MSET)
SEDAR
Management Proxy Materials
824 KB
Sep-22-2023
Mindset Pharma Inc. (CNSX:MSET)
SEDAR
Management Proxy Materials
77 KB
Sep-22-2023
Mindset Pharma Inc. (CNSX:MSET)
SEDAR
News Releases
183 KB
Sep-08-2023
Mindset Pharma Inc. (CNSX:MSET)
SEDAR
Documents Affecting the Rights of Security Holders
177 KB
Sep-08-2023
Mindset Pharma Inc. (CNSX:MSET)
SEDAR
Documents Affecting the Rights of Security Holders
177 KB
Sep-08-2023
Mindset Pharma Inc. (CNSX:MSET)
SEDAR
Documents Affecting the Rights of Security Holders
177 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Patricio L.L.B., LL.B., Richard J. (Independent Chairman)
Feb-01-2023
Common Shares
761,750
25,655
Derivative Exercise and Retained Stock
24.67
Multiple
Lanthier, James Andre-Charles (Chief Executive Officer)
Feb-01-2023
Common Shares
1,523,500
51,310
Derivative Exercise and Retained Stock
126.12
Multiple
Williams (Commerce), B.Com., B.Comm. CFA, C.F.A., CFA, Philip  (Independent Director)
Feb-01-2023
Common Shares
761,750
25,655
Derivative Exercise and Retained Stock
38.51
Multiple
Passin, James Christopher (Independent Director)
Jan-27-2023
Common Shares
761,750
25,670
Derivative Exercise and Retained Stock
33.33
Multiple
Lanthier, James Andre-Charles (Chief Executive Officer)
Aug-12-2022
Common Shares
5,000
2,566
Open Market Acquisition
0.42
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Patricio, Richard J.
Independent Chairman
416-456-6529
-
rpatricio@genericgold.ca
Araujo, Joseph 
Chief Scientific Officer, Member of Scientific Advisory Board & Director
-
-

Slassi, Abdelmalik 
Senior VP of Innovation & Member of Scientific Advisory Board
-
-

Dean, Ian 
Former Director of Preclinical & Member of Scientific Advisory Board
-
-

Gabriele, Joseph 
Member of Scientific Advisory Board
905-561-5014
-

Husain, Ishrat 
Member of Scientific Advisory Board
-
-

Kandil, Ali 
Member of Scientific Advisory Board
-
-

Passin, James Christopher
Independent Director
(646) 452-7054
-
jpassin@biovaxys.com
Rogawski, Michael 
Member of Scientific Advisory Board
-
-

Williams, Philip 
Independent Director
-
-
pwilliams@consolidateduranium.com
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Lanthier, James Andre-Charles
Chief Executive Officer
(141) 686-1168
-
jlanthier@mindsetpharma.com
Ramos, Arvin 
Chief Financial Officer
(416) 271-3877
-

Araujo, Joseph 
Chief Scientific Officer, Member of Scientific Advisory Board & Director
-
-

Atkinson, Jason 
Head of Corporate Development
416-479-4094
-
jatkinson@mindsetpharma.com
Slassi, Abdelmalik 
Senior VP of Innovation & Member of Scientific Advisory Board
-
-

Irwin, Chris 
Corporate Secretary
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
